Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Using Index Level to adjust risk lets you scale exposure in line with market momentum, maintaining a balanced, rules-based approach.
27,393 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A small AI-focused player claims it helps customers turn modest marketing spend into impressive gains. This piece bre...
A wave of roughly $150 billion in tax refunds could spark new crypto inflows. Analysts say even a modest portion movi...
A 2026 wave of disclosures shows universities reevaluating ties to Jeffrey Epstein’s fundraising network, prompting r...
The White House is clear: there will be no pardon for Bankman-Fried, even as he engages in a high-profile social medi...
Instagram will notify parents in its supervision program when their teens search suicide- or self-harm-related terms,...
Investors are weighing AMDs AI bets against its OpenAI ties and the broader AI spending boom. This guide breaks down ...
Agentic rising fast AI is changing how businesses operate, not just how we talk to machines. This article analyzes So...
Micron Technology races higher on AI memory demand and supply tightness. This piece outlines why investors may consid...
Oil prices rose above $100 a barrel after a large emergency stockpile release. Yet investor fears lingered about supp...
Two leading prediction-market platforms are pursuing high-value fundraising as U.S. lawmakers eye tighter rules. Iran...
Bill Ackman is pursuing a Berkshire Hathaway–style Pershing Square, with Amazon and Meta as core bets. The strategy h...